CSL loses a bull in Jefferies, which thinks growth in the pharmaceutical company's Vifor business appears difficult in the short term. CSL is competing with rival drugs on price, particularly from generic medication Venofer. It's also facing negative currency swings. "We continue to expect impacts from generics in the near-term, and so continue to forecast a 15% decline in FY27 Vifor iron revenue, with a resultant 300 basis-points decline in CSL Vifor Ebit margin," analyst David Stanton says. Jefferies downgrades CSL to hold, from buy. Vifor's challenges add to headwinds buffeting CSL'S Behring division, which accounts for most of its revenue. Jefferies's price target falls 45% to A$108.00/share. CSL ended Thursday at A$97.59. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

May 28, 2026 19:01 ET (23:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.